These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 1488097

  • 1. Effect of [4Cl-D-Phe6,Leu17]VIP on the inhibition of pulsatile LH release by VIP and related peptides in the ovariectomized rat.
    Weick RF, Stobie KM, Noh KA.
    Neuroendocrinology; 1992 Nov; 56(5):646-52. PubMed ID: 1488097
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal polypeptide effects a central inhibition of pulsatile luteinizing hormone secretion in ovariectomized rats.
    Alexander MJ, Clifton DK, Steiner RA.
    Endocrinology; 1985 Nov; 117(5):2134-9. PubMed ID: 3899617
    [Abstract] [Full Text] [Related]

  • 3. Effects of lesions of the suprachiasmatic and paraventricular nuclei on the inhibition of pulsatile luteinizing hormone release by exogenous vasoactive intestinal peptide in the ovariectomized rat.
    Stobie KM, Weick RF.
    Neuroendocrinology; 1990 Jun; 51(6):649-57. PubMed ID: 2114001
    [Abstract] [Full Text] [Related]

  • 4. Vasoactive intestinal peptide inhibits luteinizing hormone secretion: the inhibition is not mediated by dopamine.
    Stobie KM, Weick RF.
    Neuroendocrinology; 1989 Jun; 49(6):597-603. PubMed ID: 2671777
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP.
    Pandol SJ, Dharmsathaphorn K, Schoeffield MS, Vale W, Rivier J.
    Am J Physiol; 1986 Apr; 250(4 Pt 1):G553-7. PubMed ID: 2421587
    [Abstract] [Full Text] [Related]

  • 6. Evidence that noradrenergic activity does not mediate the inhibition of luteinizing hormone secretion caused by vasoactive intestinal peptide.
    Alexander MJ, Clifton DK, Matsumoto AM, Steiner RA.
    Brain Res; 1988 Apr 05; 445(2):247-53. PubMed ID: 3130956
    [Abstract] [Full Text] [Related]

  • 7. Preoptic injection of VIP, but not of secretin or PHI, inhibits LH and stimulates prolactin secretion in the ovariectomized rat.
    Akema T, Hashimoto R, Kimura F.
    Brain Res; 1988 Feb 16; 441(1-2):367-70. PubMed ID: 3359239
    [Abstract] [Full Text] [Related]

  • 8. Role of VIP in the regulation of LH secretion in the female rat.
    Weick RF, Stobie KM.
    Neurosci Biobehav Rev; 1995 Feb 16; 19(2):251-9. PubMed ID: 7630581
    [Abstract] [Full Text] [Related]

  • 9. Suppressive action of orexin A on pulsatile luteinizing hormone secretion is potentiated by a low dose of estrogen in ovariectomized rats.
    Furuta M, Funabashi T, Kimura F.
    Neuroendocrinology; 2002 Mar 16; 75(3):151-7. PubMed ID: 11914586
    [Abstract] [Full Text] [Related]

  • 10. Effects of intracoronary infusion of the vasoactive intestinal peptide antagonist [4Cl-D-Phe6-Leu17]VIP in the awake dog.
    Quebbemann BB, Rivier J, Bache RJ.
    Peptides; 1991 Mar 16; 12(5):989-93. PubMed ID: 1800959
    [Abstract] [Full Text] [Related]

  • 11. Central administration of antiserum to vasoactive intestinal peptide delays and reduces luteinizing hormone and prolactin surges in ovariectomized, estrogen-treated rats.
    van der Beek EM, Swarts HJ, Wiegant VM.
    Neuroendocrinology; 1999 Apr 16; 69(4):227-37. PubMed ID: 10207274
    [Abstract] [Full Text] [Related]

  • 12. Corticotropin-releasing hormone mediates suppression of pulsatile luteinizing hormone secretion induced by activation of alpha-adrenergic receptors in the paraventricular nucleus in female rats.
    Tsukamura H, Nagatani S, Cagampang FR, Kawakami S, Maeda K.
    Endocrinology; 1994 Mar 16; 134(3):1460-6. PubMed ID: 8119187
    [Abstract] [Full Text] [Related]

  • 13. Influence of [4Cl-D-Phe6,Leu17]VIP on VIP- and central TRH-induced gastric hyperemia.
    Király A, Sütó G, Guth P, Taché Y.
    Peptides; 1997 Mar 16; 18(9):1321-5. PubMed ID: 9392832
    [Abstract] [Full Text] [Related]

  • 14. Role of neuropeptide-Y in episodic luteinizing hormone release in ovariectomized rats: an excitatory component and opioid involvement.
    Xu B, Sahu A, Crowley WR, Leranth C, Horvath T, Kalra SP.
    Endocrinology; 1993 Aug 16; 133(2):747-54. PubMed ID: 8344213
    [Abstract] [Full Text] [Related]

  • 15. Decrease of rapid-eye-movement sleep in the light by intraventricular application of a VIP-antagonist in the rat.
    Mirmiran M, Kruisbrink J, Bos NP, Van der Werf D, Boer GJ.
    Brain Res; 1988 Aug 16; 458(1):192-4. PubMed ID: 3208098
    [Abstract] [Full Text] [Related]

  • 16. Interaction of peptides related to VIP and secretin with guinea pig pancreatic acini.
    Zhou ZC, Gardner JD, Jensen RT.
    Am J Physiol; 1989 Feb 16; 256(2 Pt 1):G283-90. PubMed ID: 2465694
    [Abstract] [Full Text] [Related]

  • 17. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity.
    Sirianni MC, Annibale B, Tagliaferri F, Fais S, De Luca S, Pallone F, Delle Fave G, Aiuti F.
    Regul Pept; 1992 Mar 05; 38(1):79-87. PubMed ID: 1574603
    [Abstract] [Full Text] [Related]

  • 18. Vasoactive intestinal peptide modulates luteinizing hormone subunit gene expression in the anterior pituitary in female rat.
    Gajewska A, Wolińska-Witort E, Kochman K.
    Brain Res Bull; 2005 Oct 30; 67(4):319-26. PubMed ID: 16182940
    [Abstract] [Full Text] [Related]

  • 19. Lack of effect of vasoactive intestinal peptide antagonists on blood flow in the rat thyroid.
    Michalkiewicz M, Huffman LJ, Hedge GA.
    Peptides; 1991 Oct 30; 12(6):1181-6. PubMed ID: 1815206
    [Abstract] [Full Text] [Related]

  • 20. Bicarbonate secretion in the guinea pig duodenum: functional characterization of peptide hormone receptors in duodenal enterocytes.
    Reimer R, Odes HS, Beil W, Schwenk M, Muallem R, Sewing KF.
    Pharmacology; 1996 Jun 30; 52(6):339-46. PubMed ID: 8844783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.